# GLOW peptide dosage in the research context: constituent figures only > GLOW peptide dosage has no validated standard — the blend has never been dosed in a controlled human trial. Only constituent research figures and handling context exist, presented for context only. The GLOW peptide dosage question has no controlled-trial answer. What follows is constituent-level research data and general handling context, never a protocol. ## GLOW peptide dosage in the research context GLOW peptide dosage cannot be stated as a validated figure, because the blend has never been dosed in a controlled human trial. Any number below is either constituent-level research data or a non-validated community or clinic convention, presented for context only and never as a recommendation. The constituent research figures span orders of magnitude and routes, which is itself the point: there is no single unit in which a "GLOW dose" could be expressed. GHK-Cu drives fibroblast collagen synthesis in vitro at roughly 10⁻¹² to 10⁻⁹ M — picomolar to nanomolar concentrations in cell culture — and topical cosmetic formulations run about 0.05% to 2% (w/w) [1][2]. BPC-157's rodent tissue-repair studies used roughly 10 ng to 10 µg per rat per day intraperitoneally [3], and the same Achilles-tendon work tested doses three orders of magnitude apart (10 µg, 10 ng and 10 pg/kg) [3], while a first-in-human IV safety pilot used 10 mg then 20 mg in two adults [11]. For the thymosin beta-4 family, a human Phase 1 study gave full-length protein intravenously at 42, 140, 420 and 1260 mg, escalating across four dose tiers [6]. A commonly cited research-label blend ratio is 10 mg BPC-157 / 10 mg TB-500 / 50 mg GHK-Cu per vial — a supplier labeling convention, not a clinically validated dose. Notice that those milligram figures bear no fixed relationship to the in-vitro concentrations, topical percentages and per-kilogram animal doses above: a vial label is a packaging decision, not a translation of any study. These figures do not combine into a blend dose, and this site does not present them as one. For the regulatory frame around access, see the [GLOW legal status and FDA 503A category](/legal-status). ## Half-life and what is known about clearance No pharmacokinetic data exist for the GLOW blend as a unit; combination PK has never been characterized. The constituents differ widely. BPC-157 has a short elimination half-life — under 30 minutes in rats and dogs — with linear kinetics and rapid breakdown to amino acids. The free GHK tripeptide is cleared rapidly by plasma peptidases, while topical GHK-Cu instead forms a dermal copper depot rather than circulating [7]. Thymosin beta-4 showed dose-proportional pharmacokinetics with half-life increasing at higher doses in its human Phase 1 study [6]. Whether co-formulation alters any constituent's kinetics is unstudied. Three molecules with three clearance profiles, combined in one vial, do not yield a single predictable half-life, and none has been measured for the blend. ## GLOW peptide injection: routes studied and the absence of blend pharmacology Routes for GLOW are constituent routes only. GHK-Cu is predominantly topical — creams, serums, microneedle and liposomal delivery — with rodent intraperitoneal and intranasal systemic studies [1][2][7]. BPC-157 has been given intraperitoneally and intramuscularly in animals and intravenously in the 2-subject human pilot [3][11]. Thymosin beta-4 has been studied topically and intraperitoneally in animals and intravenously in human Phase 1 [5][6]. The GLOW peptide injection question follows from this directly: community GLOW protocols describe subcutaneous injection of the reconstituted blend, but no peer-reviewed pharmacology supports subcutaneous blend dosing. There is no controlled study of an injected three-peptide GLOW combination, so any injection protocol is a community convention without published blend pharmacology behind it. #### How do you reconstitute GLOW peptide? Lyophilized peptide blends are reconstituted with bacteriostatic water and refrigerated; this is general research-handling context, not a dosing instruction. The GLOW blend's stability when co-formulating a copper complex with two peptides is uncharacterized, and bacteriostatic water contains 0.9% benzyl alcohol to inhibit bacterial growth over multiple uses. #### How much bacteriostatic water for GLOW peptide? Reconstitution volume is a research-handling choice that depends on the vial's stated peptide mass and is not a validated dose. No clinical protocol defines a blend concentration, and all such figures are presented as context only. ## Stability: the open question of co-formulating copper with peptides Blend stability is formulation-specific and uncharacterized in the literature. The constituent notes are instructive. The GHK-Cu complex is most stable near pH 5-6.5, and its blue-violet color indicates an intact Cu(II) complex; strong reducing agents and low-pH actives such as ascorbic acid can break it, releasing the copper from the tripeptide and ending the matrix-signaling form that the skin research describes [1]. Lyophilized BPC-157 and TB-500 are reconstituted with bacteriostatic water and refrigerated, standard research handling for freeze-dried peptides. The complication is what happens when all three share a vial. Co-formulating a copper complex with two other peptides raises theoretical compatibility questions — copper redox chemistry, pH windows that suit one constituent but not another, and the possibility that the conditions keeping GHK-Cu intact are not the conditions in which the other two peptides are most stable — none of which has been studied for GLOW specifically. This is one more place where reading GLOW as a single product obscures real uncertainty: the chemistry of the mixture is simply not established, and a label cannot stand in for stability data that does not exist. Anyone weighing the [GLOW peptide safety research](/safety-research) should read the absence of blend stability data as part of that picture. --- A pressed-botanical reading of the GLOW peptide record — each constituent study labeled by what it can bear and where it stops, with no clinic behind the specimen sheet and nothing here dispensed.